Pacira BioSciences Inc (NASDAQ: PCRX) stock suffered a major decline of -20.1% on 7/2/24. The shares closed at $22.74. Moreover, exceptionally high trading volume at 880% of normal accompanied the decline. Relative to the market the stock has been weak over the last nine months and has declined -21.7% during the last week.
Current PriceTarget Research Rating
With future capital returns forecasted to be above the cost of capital, PCRX is expected to continue to be an important Value Builder.
Pacira BioSciences has a current Value Trend Rating of C (Neutral). With this rating, PTR’s two proprietary measures of a stock’s current attractiveness are providing contradictory signals. Pacira BioSciences has a slightly positive Appreciation Score of 62 but a slightly negative Power Rating of 35, leading to the Neutral Value Trend Rating.
Rating Review
In light of this highly negative price change we are reviewing our current Overall Rating of C. This review will be completed in the next several days.
Be the first to comment